Scientific Literature Search

Source record

Contributions of VPS35 Mutations to Parkinson's Disease.

Rahman AA, Morrison BE.

Neuroscience · 2019-01-18

DOI: 10.1016/j.neuroscience.2019.01.006PMID: 30660673

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease.

Baul HS, Manikandan C, Sen D.

Brain Res Bull · 2019-01-18

DOI: 10.1016/j.brainresbull.2019.01.016PMID: 30664919

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Modified Mindfulness-Based Cognitive Therapy for Depressive Symptoms in Parkinson's Disease: a Pilot Trial.

Rodgers SH, Schütze R, Gasson N, Anderson RA, Kane RT, Starkstein S, Morgan-Lowes K, Egan SJ.

Behav Cogn Psychother · 2019-01-18

DOI: 10.1017/s135246581800070xPMID: 30654854

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Long-term outcomes following deep brain stimulation for Parkinson's disease.

Hitti FL, Ramayya AG, McShane BJ, Yang AI, Vaughan KA, Baltuch GH.

J Neurosurg · 2019-01-18

DOI: 10.3171/2018.8.jns182081PMID: 30660117

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Open access

Deep brain stimulation for monogenic Parkinson's disease: a systematic review.

Kuusimäki T, Korpela J, Pekkonen E, Martikainen MH, Antonini A, Kaasinen V.

J Neurol · 2019-01-18

DOI: 10.1007/s00415-019-09181-8PMID: 30659355

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Predictive markers for Parkinson’s disease using deep neural nets on neuromelanin sensitive MRI

Shinde S, Prasad S, Saboo Y, Kaushick R, Saini J, Pal PK, Ingalhalikar M.

· 2019-01-17

DOI: 10.1101/523100

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Submicron Crystals of the Parkinson’s Disease <i>Substantia nigra</i> : Calcium Oxalate, Titanium Dioxide and Iron Oxide

Heller A, Coffman SS.

· 2019-01-17

DOI: 10.1101/523878

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Open access

Central modulation of parasympathetic outflow is impaired in de novo Parkinson's disease patients.

Tessa C, Toschi N, Orsolini S, Valenza G, Lucetti C, Barbieri R, Diciotti S.

PLoS One · 2019-01-17

DOI: 10.1371/journal.pone.0210324PMID: 30653564

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Open access

Five-Year Clinical Outcomes of Local versus General Anesthesia Deep Brain Stimulation for Parkinson's Disease.

Tsai ST, Chen TY, Lin SH, Chen SY.

Parkinsons Dis · 2019-01-17

DOI: 10.1155/2019/5676345PMID: 30800263

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Open access

Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.

Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C, the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee.

Mov Disord · 2019-01-17

DOI: 10.1002/mds.27602PMID: 30653247

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.

Warren Olanow C, Torti M, Kieburtz K, Leinonen M, Vacca L, Grassini P, Heller A, Heller E, Stocchi F.

Mov Disord · 2019-01-17

DOI: 10.1002/mds.27610PMID: 30653246

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Risk of Parkinson's disease dementia related to level I MDS PD-MCI.

Hoogland J, Boel JA, de Bie RMA, Schmand BA, Geskus RB, Dalrymple-Alford JC, Marras C, Adler CH, Weintraub D, Junque C, Pedersen KF, Mollenhauer B, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ, MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord · 2019-01-17

DOI: 10.1002/mds.27617PMID: 30653248

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Records come from scientific sources. Bibliographic counts do not represent completed translations or editorial approvals.

106.962 articles found

Contributions of VPS35 Mutations to Parkinson's Disease.

Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease.

Modified Mindfulness-Based Cognitive Therapy for Depressive Symptoms in Parkinson's Disease: a Pilot Trial.

Long-term outcomes following deep brain stimulation for Parkinson's disease.

Deep brain stimulation for monogenic Parkinson's disease: a systematic review.

Predictive markers for Parkinson’s disease using deep neural nets on neuromelanin sensitive MRI

Submicron Crystals of the Parkinson’s Disease <i>Substantia nigra</i> : Calcium Oxalate, Titanium Dioxide and Iron Oxide

Central modulation of parasympathetic outflow is impaired in de novo Parkinson's disease patients.

Five-Year Clinical Outcomes of Local versus General Anesthesia Deep Brain Stimulation for Parkinson's Disease.

Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.

Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.

Risk of Parkinson's disease dementia related to level I MDS PD-MCI.

Filters